Pharma / Biotech

Synthesis and preliminary evaluation of 99mTc-Hynic-fragments [F(ab')2 and F(ab')] of Rituximab as radioimmunoscintigraphic agents for patients with Non-Hodgkin's lymphoma.

Synthesis and preliminary evaluation of 99mTc-Hynic-fragments [F(ab’)2 and F(ab’)] of Rituximab as radioimmunoscintigraphic agents for patients with Non-Hodgkin’s lymphoma.

Appl Radiat Isot. 2019 Jul 12;153:108808

Authors: Suman SK, Kameswaran M, Mallia M, Mittal S, Dash A

Abstract
This study was to evaluate the potential of 99mTc-Hynic-fragments of Rituximab as radioimmunoscintigraphic agents for diagnosis of patients with Non-Hodgkin’s Lymphoma (NHL). Rituximab was digested with immobilized pepsin and papain to yield F(ab’)2-Rituximab and F(ab’)-Rituximab fragments respectively. Purified fragments were characterized by SE-HPLC and SDS-PAGE and subsequently radiolabeled with technetium-99m using Hynic as bifunctional chelator. The 99mTc-Hynic-F(ab’)2-Rituximab and 99mTc-Hynic-F(ab’)-Rituximab exhibited good in-vitro stability and specificity to Raji cells. Biodistribution studies demonstrated rapid pharmacokinetics and clearance predominantly through renal route.

PMID: 31325798 [PubMed – as supplied by publisher]

Source link




Related posts

Icosahedral boron clusters as modifying entities for biomolecules.

Newsemia

ELETRIPTAN HYDROBROMIDE Tablet, Film Coated [Mylan Pharmaceuticals Inc.]

Newsemia

clinical pharmacology; +342 new citations

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy